Search | IOVS | ARVO Journals

View

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

RNA Structure-Function Properties of Enhanced Hammerhead Ribozymes with High Catalytic Efficiency

Jack M Sullivan; Jason Myers

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):78 – A0051. doi:

ARVO Annual Meeting Abstract June 2022

Synthetic Nuclease Resistant Enhanced Hammerhead Ribozymes for Nucleic Acid Ocular Therapeutics

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):55 – A0028. doi:

ARVO Annual Meeting Abstract June 2021

Enhanced Hammerhead Ribozymes as Synthetic Nucleic Acid Ocular Therapeutics

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1203. doi:

ARVO Annual Meeting Abstract June 2020

RNA Structure-Function Properties in Facilitated Hammerhead Ribozymes with Unprecedented Catalytic Rates

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2293. doi:

ARVO Annual Meeting Abstract June 2020

A Facilitated Hammerhead Ribozyme Rhodopsin Therapeutic with Catalytic Efficiency on Par with Ribonuclease A at Cellular Free Mg 2+ Levels

Jack M Sullivan; Jason Myers

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4481. doi:

ARVO Annual Meeting Abstract July 2019

Discovery of a Hammerhead Ribozyme with Enzyme Kinetics comparable to Protein Enzymes

Jason Myers; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3406. doi:

ARVO Annual Meeting Abstract July 2019

Facilitated Hammerhead Ribozymes- A New Therapeutic Modality for Inherited Retinal Degenerations

Jack M Sullivan; Jason Myers; Alexandria Trujillo; Mark Christian Butler; Zahra Fayazi; Jibin A. Punnoose; Kenneth A. Halvorsen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3412. doi:

ARVO Annual Meeting Abstract July 2018

A Novel Hammerhead Ribozyme with High Catalytic Activity at Physiological Free Mg 2+ Levels: A Potential Therapeutic for Autosomal Dominant Retinitis Pigmentosa

Jason Myers; Zahra Fayazi; Mark Christian Butler; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):380. doi:

ARVO Annual Meeting Abstract July 2018

Comparison of Efficacy of Various shRNAs Targeting Human RHO mRNA in Cultured Cells as Model Therapeutics for Autosomal Dominant Retinitis Pigmentosa

Zahra Fayazi; Jason Myers; Mark Christian Butler; Alexandria J Trujillo; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4544. doi:

ARVO Annual Meeting Abstract July 2018

Novel Approach to treat Wet Age-Related Macular Degeneration (wAMD) and other Retinal Vascular Diseases

Mark Christian Butler; Upendra Chitgupi; Jason Myers; Matthew D. Anger; Jonathan Lovell; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5665. doi:

ARVO Annual Meeting Abstract June 2017

Hammerhead ribozyme in a tRNA scaffold: Effects of RNA processing and anti-sense flank length on cleavage in-vivo

Jason Myers; Zahra Fayazi; Mark Christian Butler; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4496. doi:

ARVO Annual Meeting Abstract September 2016

Quantitative Outer Retinal Light Damage in Stargardt-AMD Mouse Model

Jason M Myers; Mark Christian Butler; Jack M Sullivan

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):779. doi:

ARVO Annual Meeting Abstract June 2013

Metabotropic glycine receptors can enhance bipolar cell output in rat retina

Jay Garaycochea; Malcolm Slaughter; Jason Myers

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6149. doi:

ARVO Annual Meeting Abstract April 2011

Multiple Sweet Sensing Systems In Rat Retina

Jaeyoung Yang; Jason Myers; Malcolm M. Slaughter

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4133. doi:

Advertisement